HRES 1154 · 115th Congress 2017–2019, ended

Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.

Latest action · Nov 16, 2018 Referred to the House Committee on Energy and Commerce.

Progress

Where this resolution reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried. A simple resolution is the business of one chamber alone: it is not sent to the other chamber or to the President, and does not become law.

  1. IntroducedNov 16, 2018
  2. Agreed to in HouseNot reached

Summary

Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.

Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.

Cosponsors 3

Members who signed on, in the order they did. Signatures ran from Nov 16, 2018 to Nov 27, 2018; 2 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-CAAnna G. EshooOriginalNov 16, 2018
D-NCG. K. ButterfieldOriginalNov 16, 2018
D-INAndré CarsonNov 27, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Nov 16, 2018

Actions 2

Everything that happened, newest first.

  1. Nov 16, 2018Introduced in House
  2. Nov 16, 2018Referred to the House Committee on Energy and Commerce.

Related bills 1

Companion bills and other measures the record links to this one.

Titles 1

Every title it has carried, official and short, at each stage.

Official Title as Introduced
Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Nov 16, 2018Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this resolution on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.